David Bak­er’s lab and ARCH sprout Lord of the Rings-in­spired macro­cy­cle biotech

3 years ago
Financing

As­traZeneca’s Pas­cal So­ri­ot says Covid-19 boost­ers may not be for every­one — re­port

3 years ago
Coronavirus

As Hori­zon works to beef up drug sales, CEO Wal­bert maps a big man­u­fac­tur­ing ex­pan­sion in Ire­land, 350 new jobs

3 years ago
Manufacturing

Af­ter years of fail­ures, the hunt for a new type of Parkin­son’s drug is on

3 years ago
R&D
In Focus

#ESC22: Bay­er's chron­ic kid­ney dis­ease drug miss­es the mark on low­er­ing car­dio­vas­cu­lar death

3 years ago
R&D
Pharma

#ESC22: Cin­Cor CMO’s 17-year jour­ney in bring­ing a new hy­per­ten­sion drug to mar­ket con­tin­ues

3 years ago
R&D

#ESC22: BMS-J&J’s mil­vex­i­an miss­es com­pos­ite end­point, but duo to push drug for­ward with signs of sec­ondary stroke ...

3 years ago
R&D
Pharma

#ESC22: Bay­er's fac­tor XIa in­hibitor miss­es ef­fi­ca­cy marks in 2 PhII stud­ies but com­pa­ny dives straight in­to PhI­II

3 years ago
R&D
Pharma

#ESC22: ‘Anx­ious for more ev­i­dence’: As­traZeneca touts DE­LIV­ER da­ta in bid to ex­pand Farx­i­ga’s heart fail­ure ...

3 years ago
R&D
Pharma

Mod­er­na goes on the patent of­fen­sive; Pablo Legor­re­ta dou­bles down; Is a biotech re­cov­ery on the way?; and more

3 years ago
Weekly

Gilead fights back against BMS Supreme Court pe­ti­tion in patent fight

3 years ago
Pharma
Law

Drug man­u­fac­tur­ers must sub­mit re­ports on qual­i­ty prob­lems to FDA. Al­most half of sites still don't, new re­port finds

3 years ago
FDA+
Manufacturing

In­cyte se­cures sec­ond FDA ap­proval for bile duct can­cer drug in mu­tat­ed can­cer type

3 years ago
Pharma
FDA+

With two new ex­pen­sive gene ther­a­py ap­provals, out­comes-based pric­ing deals grab the spot­light again

3 years ago
R&D
Pharma

No­var­tis turns to re­al metasta­t­ic breast can­cer pa­tient for ‘first gen­er­a­tion’ Kisqali TV ad

3 years ago
Pharma
Marketing

US and Chi­na de­vel­op frame­work for in­spec­tion of 200 US-list­ed com­pa­nies un­der threat of delist­ing

3 years ago
China
Pharma

Ab­b­Vie scores a key win in Alzheimer's drug patent suit

3 years ago
Law

Up­dat­ed: Mod­er­na sues Pfiz­er and BioN­Tech for in­fring­ing on mR­NA vac­cine patents used in block­buster Covid shots

3 years ago
R&D
Law

Coin flip: Top an­a­lyst gives Amy­lyx ALS drug a 50% chance at ap­proval as rare sec­ond ad­comm ap­proach­es

3 years ago
R&D
FDA+

Small neu­rol­o­gy biotech an­nounces prices its $8M IPO; Vivos put on no­tice af­ter miss­ing fil­ing dead­line

3 years ago
News Briefing

Af­ter Chi­na Trodelvy OK, Ever­est Med­i­cines CEO re­signs and the hunt is on for his re­place­ment

3 years ago
People

Ae­glea re­places CEO as com­pa­ny is set to cut more em­ploy­ees, change strat­e­gy

3 years ago
People

Take­da breaks off five-year pact with mi­cro­bio­me part­ner, hand­ing back two pre­clin­i­cal drugs

3 years ago
Deals

No deal for Mer­ck and Seagen yet as talks stall over buy­out price — re­port

3 years ago
Deals
First page Previous page 466467468469470471472 Next page Last page
A service from the Financial Times